Active Targeted Nanoparticles for Oral Administration of Gastric Cancer Therapy.
Gastric carcinogenesis is a commonly diagnosed type of cancer and has a dismal prognosis because of the rate at which it aggressively spreads and because of the lack of effective therapies to stop its progression. This study evaluated a type of oral drug delivery system of a potential target-activated nanosizer comprising a fucose-conjugated chitosan and polyethylene glycol-conjugated chitosan complex with gelatin containing encapsulated green tea polyphenol extract epigallocatechin-3-gallate, allowing oral administration of the drug through a site-specific release in gastric cancer cells. The results demonstrated that the nanoparticles effectively reduced drug release within gastric acids and that a controlled epigallocatechin-3-gallate release inhibited gastric cancer cell growth, induced cell apoptosis, and reduced vascular endothelial growth factor protein expression. Furthermore, in vivo assay results indicated that the prepared epigallocatechin-3-gallate-loaded fucose-chitosan/polyethylene glycol-chitosan/gelatin nanoparticles significantly affected gastric tumor activity and reduced gastric and liver tissue inflammatory reaction in an orthotopic gastric tumor mouse model.
Department of Biological Science and Technology, China Medical University , Taichung, Taiwan.|Department of Urology, University of Texas Southwestern Medical Center , Dallas, Texas 75390, United States.
Yu-Hsin
YH
Lin
Department of Biological Science and Technology, China Medical University , Taichung, Taiwan.
Zih-Rou
ZR
Chen
Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, Chang Gung University , Taoyuan, Taiwan.|Graduate Institute of Basic Medical Science & School of Medicine, China Medical University , Taichung, Taiwan.
Chih-Ho
CH
Lai
Graduate Institute of Basic Medical Science, China Medical University , Taichung, Taiwan.
Chia-Hung
CH
Hsieh
Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital , Taichung, Taiwan.
Chun-Lung
CL
Feng
D000284:Administration, Oral; D000818:Animals; D017209:Apoptosis; D002392:Catechin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D048271:Chitosan / Q000737:chemistry / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry / Q000494:pharmacology; D005780:Gelatin / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D004337:Drug Carriers; D011092:Polyethylene Glycols; D002392:Catechin; D005780:Gelatin; D048271:Chitosan; C045651:epigallocatechin gallate; C000595209:polyethylene glycol 1000